Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria

J Allergy Clin Immunol. 2017 Dec;140(6):1749-1751. doi: 10.1016/j.jaci.2017.08.007. Epub 2017 Sep 1.

Authors

Ragip Ertas¹, Kemal Ozyurt¹, Emin Ozlu¹, Yilmaz Ulas¹, Atil Avci¹, Mustafa Atasoy¹, Tomasz Hawro², Marcus Maurer³

Affiliations

¹ Saglik Bilimleri University, Kayseri Education and Research Hospital Dermatology Clinic, Kayseri, Turkey.
² Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany.
³ Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany. Electronic address: [email protected].

PMID: 28870460
DOI: 10.1016/j.jaci.2017.08.007

No abstract available

Publication types

Letter
Observational Study

MeSH terms

Adult
Anti-Allergic Agents / therapeutic use*
Chronic Disease
Female
Humans
Immunoglobulin E / blood*
Male
Medication Adherence
Middle Aged
Omalizumab / therapeutic use*
Recurrence
Urticaria / blood*
Urticaria / drug therapy*
Young Adult

Substances

Anti-Allergic Agents
Omalizumab
Immunoglobulin E